Long-term safety analysis of pooled data for tislelizumab as monotherapy or in combination with chemotherapy in patients with advanced cancers
Tislelizumab's safety profile, as monotherapy or combined with chemotherapy, remains consistent with previous reports across tumor types. Delayed imAEs were relatively infrequent, with no new signals identified in this long-term safety analysis.
Authors
- Caicun Zhou (ORCID: https://orcid.org/0000-0002-6958-0766)
- Patrick Schnell (ORCID: https://orcid.org/0009-0001-8483-9764)
- Jaffer A. Ajani (ORCID: https://orcid.org/0000-0001-9946-0629)
- Jola Mehmeti
- Alysha Kadva (ORCID: https://orcid.org/0000-0002-2637-8373)
- John Y. Wu
- Yuan Yuan
- Rose Huang
Institutions
- National Park Service (US)
- The University of Texas MD Anderson Cancer Center (US)
- Samsung (United States) (US)
- Building Engineering and Science Talent (US)
- Shanghai East Hospital (CN)
- Drug Safety Research Unit (GB)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-06-27
- DOI
- https://doi.org/10.1093/oncolo/oyaf177
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Eli Lilly and Company
- Sanofi
- Innovent Biologics